MedTrace Logo

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

NCT01838239 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-05-30

No results posted yet for this study

Summary

The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN) and in healthy subjects. The hypothesis is that measuring variation among individuals and changes in response to omega-3 fatty acids comprehensively by using metabolomics will help to identify those individuals who are responders and those who are non-responders to omega-3 fatty acids as an anti-inflammatory intervention.

Conditions

  • Immunoglobulin A Nephropathy
  • Healthy Subjects

Interventions

DIETARY_SUPPLEMENT

Fish Oil

Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Bruce D Hammock, PhD · University of California, Davis

  • Angela M Zivkovic, PhD · University of California, Davis

  • J. Bruce German, PhD · University of California, Davis

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2010-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01838239 on ClinicalTrials.gov